Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America, July 2022 JPGN
- Registration Closed
Already registered?
Log in now.
Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America, July 2022 JPGN
Key:
Complete
Next
Failed
Available
Locked
CME Requirements and Learning Objectives: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America, July 2022 JPGN
Open to download resource.
Open to download resource.
Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
Open to download resource.
Open to download resource.
Post-Test: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
3 Questions | Unlimited attempts | 2/3 points to pass
3 Questions | Unlimited attempts | 2/3 points to pass
Post-Webinar Evaluation: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
14 Questions
14 Questions
Post-Webinar Evaluation: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America